+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
All Ages
All Genders
Healthy Volunteers
ID06648044

Research on Therapeutic Targets for Nephronophthisis and Related Renal Ciliopathies to Identify New Treatments and Biomarkers

Led by Imagine Institute · Updated on 2026-10-05

310

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Nephronophthisis NPH is a genetic disease caused by mutations in over 20 genes, including NPHP1 and NPHP4. It leads to reduced urine concentration, chronic kidney inflammation, and progresses to kidney failure before age 20. NPH can occur alone or with other symptoms affecting the eyes, brain, skeleton, or organ placement. Currently, there is no effective treatment for NPH or related renal ciliopathies. This research studies therapeutic targets by analyzing proteins and signaling pathways involved in NPH. Approved drugs that correct defects found in cells with NPHP mutations have been identified. Participants include affected patients, healthy relatives, and control groups. Blood and urine samples are collected for multiomics analyses to identify biomarkers and monitor drug responses in kidney cells. Participants provide samples which undergo proteome, miRNAome, and metabolomics profiling. Researchers measure therapeutic targets confirmed in urine-derived kidney cells over three years. The study also collects experimental data from cell models and ranks druggable targets for NPH. This long-term research aims to develop new treatments and biomarkers to improve management of NPH and renal ciliopathies.

CONDITIONS

Brief Title

Research of Therapeutic Targets in the Frame of Nephronophthisis and Renal Associated Ciliopathies

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here